Inovio Pharmaceuticals (NASDAQ:INO) Share Price Passes Above 50-Day Moving Average of $2.75

Inovio Pharmaceuticals Inc (NASDAQ:INO)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.75 and traded as high as $2.97. Inovio Pharmaceuticals shares last traded at $2.94, with a volume of 7,231 shares.

INO has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, April 3rd. HC Wainwright set a $4.00 price objective on shares of Uranium Energy and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Zacks Investment Research lowered shares of Hanger from a “hold” rating to a “sell” rating in a research note on Tuesday, May 28th. Cantor Fitzgerald initiated coverage on shares of Inovio Pharmaceuticals in a research note on Monday, March 25th. They issued an “overweight” rating and a $3.62 price objective for the company. Finally, BidaskClub downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $7.22.

The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02. The company has a market cap of $293.12 million, a P/E ratio of -2.85 and a beta of 2.03. The business has a 50-day moving average of $2.75.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. The company had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $4.44 million. As a group, research analysts predict that Inovio Pharmaceuticals Inc will post -1.01 EPS for the current year.

In other news, CEO Jong Joseph Kim sold 2,129,553 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $2.36, for a total transaction of $5,025,745.08. Following the transaction, the chief executive officer now owns 1,911,055 shares in the company, valued at approximately $4,510,089.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Laurent Humeau purchased 20,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $50,000.00. Following the acquisition, the insider now directly owns 45,833 shares in the company, valued at approximately $114,582.50. The disclosure for this purchase can be found here. Insiders have sold a total of 2,866,321 shares of company stock worth $7,055,433 in the last 90 days. 7.90% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in INO. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals in the 1st quarter worth $40,000. Amalgamated Bank bought a new position in Inovio Pharmaceuticals in the 4th quarter worth $50,000. M Holdings Securities Inc. bought a new position in Inovio Pharmaceuticals in the 1st quarter worth $54,000. Paloma Partners Management Co raised its holdings in Inovio Pharmaceuticals by 38.7% in the 4th quarter. Paloma Partners Management Co now owns 16,201 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 4,522 shares during the period. Finally, BNP Paribas Arbitrage SA raised its holdings in Inovio Pharmaceuticals by 58,648.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 18,212 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 18,181 shares during the period. Institutional investors and hedge funds own 47.24% of the company’s stock.

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

See Also: What is a growth and income fund?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.